At the news
? NEUTRALIMPACT 3/10 PTAB-TRIAL filed Nov 9, 2026 at 19:00 ET
The PTAB granted institution of IPR2026-00260, allowing Amneal and Kashiv to challenge claims of Novartis's patent covering anti-IgE antibody therapy for multiple food allergies. As an interlocutory ruling, no claims have been cancelled, and the patent remains in force pending a final written decision.
- PTAB granted institution of IPR2026-00260 on November 10, 2026
- Patent U.S. 12030959 covers anti-IgE antibody therapy for multiple food allergies
- Patent owner is Genentech Inc. and Novartis Pharmaceuticals Corp. (Novartis AG subsidiary)
- Petitioners are Amneal Pharmaceuticals, Inc. and Kashiv Biosciences, LLC
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access